Brief: NGM Announces Completion Of Enrollment In Phase 2 Catalina Study Of Ngm621 In Patients With Geographic Atrophy Secondary To Age-Related Macular Degeneration
22/07/2021 21:49
July 22 (Reuters) - NGM Biopharmaceuticals Inc NGM.O :
* NGM ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 CATALINA
STUDY
OF NGM621 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO
AGE-RELATED MACULAR DEGENERATION
* NGM BIOPHARMACEUTICALS INC - ANTICIPATES PHASE 2 CATALINA
STUDY
TOPLINE DATA READOUT IN SECOND HALF OF 2022
Source text for Eikon: ID:nGNX49RTp8
Further company coverage: NGM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NGM Biopharmaceuticals
See all newsBrief: NGM Biopharmaceuticals Q4 Net Income USD -27.67 Million
Brief: NGM Bio Enters into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group
NGM Biopharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Ngm Biopharmaceuticals Says It Got Written Notice From Nasdaq Informing It Has Regained Compliance With Nasdaq Listing
Brief: NGM Bio Announces New Clinical Data From Ongoing Trial Of Ngm707 In Advanced Solid Tumors